When reading “Fazekas 2” on a brain MRI report, the first reaction is often concern. This score, which qualifies lesions of the brain’s white matter related to small vessel damage, corresponds to an intermediate stage on the Fazekas scale. Neither trivial nor catastrophic, it indicates an already established cerebral microangiopathy that requires structured follow-up and concrete therapeutic decisions.
Fazekas 2 and small vessel disease: what the MRI does not say alone
The Fazekas scale classifies white matter hyperintensities into four levels (0 to 3). A score of 2 indicates moderate confluent lesions, visible as white patches on the FLAIR sequences of the MRI. These are distinguished from simple isolated points of stage 1.
See also : Everything You Need to Know About CAPTVTY
What many patients do not know is that the Fazekas score alone is not sufficient to assess the actual severity of the situation. Recent recommendations in neuroradiology encourage complementing this classification with other MRI markers of small vessel disease.
- Microbleeds, which indicate advanced vascular fragility and modify the prognosis.
- Cerebral lacunes, small cavitary sequelae of silent infarcts, often associated with gait disturbances.
- Dilation of perivascular spaces and the degree of cortico-subcortical atrophy, which refine the estimation of cognitive risk.
A patient classified as Fazekas 2 with several microbleeds and lacunes does not have the same prognosis as a Fazekas 2 patient without other anomalies. It is this combined reading that guides the neurologist towards close monitoring or simple observation.
You may also like : Everything You Need to Know About Motocross: Tips, Gear, and Off-Road Passion
This is why it is recommended to delve deeper into the diagnosis and treatment of Fazekas 2 vascular leukopathy beyond the simple score displayed on the report.
Neurological follow-up at Fazekas 2 stage: frequency and warning signs
Some neurologists now consider Fazekas 2 stage as a marker of already established small vessel disease, rather than just a simple intermediate stage to be passively monitored. The current trend is to propose consultations every six to twelve months, with a follow-up MRI to assess the progression of lesions.
This follow-up rhythm is not systematic everywhere, and practices vary by center. However, certain signals should trigger an urgent consultation or an early check-up:
Recent or worsening gait disturbances, new postural instability, repeated falls. These symptoms, often attributed to aging, may actually indicate a progression of microangiopathy.
New cognitive difficulties, particularly regarding executive functions: planning a task, managing multiple pieces of information simultaneously, following a complex conversation. Memory is not always the first sign affected, contrary to what many fear when thinking of Alzheimer’s disease.
Episodes of brief confusion, mood changes, or unusual apathy should also be reported to the neurologist.
Treatment of Fazekas 2 vascular leukopathy: blood pressure control and beyond
There is no treatment that can eliminate already established white matter lesions. The therapeutic goal is to slow the progression of cerebral microangiopathy and limit the onset of new symptoms.
Strict control of vascular risk factors
Blood pressure is the main lever. Poorly controlled hypertension accelerates the degradation of small cerebral vessels. The physician adjusts antihypertensive treatment to aim for strict blood pressure targets, considering the patient’s tolerance (risk of orthostatic hypotension, especially in the elderly).
Other vascular risk factors, such as diabetes, cholesterol, and smoking, are integral to management. All levers are acted upon in parallel.
Review of prescriptions: a often overlooked angle
Recent publications in geriatrics and neurology emphasize a point rarely discussed with patients: the cumulative effect of sedative psychotropics on gait and cognition in individuals with Fazekas 2 leukopathy. Benzodiazepines, anticholinergics, and neuroleptics can worsen balance disorders and cognitive difficulties already favored by vascular lesions.
The recommendation is to integrate a systematic review of prescriptions into the therapeutic strategy, on par with blood pressure control. Specifically, this means a cautious deprescribing of sedative medications, in consultation with the primary care physician and the neurologist.
Fazekas 2 leukopathy and the risk of vascular dementia: what we know
The main fear of patients remains progression to dementia. Fazekas 2 stage is associated with an increased risk of stroke and vascular dementia, regardless of age. This is not a fatality, but a signal that justifies active management.
Not all vascular leukopathies lead to dementia. The prognosis depends on the combination of MRI markers (presence or absence of lacunes, microbleeds), control of risk factors, and the quality of neurological follow-up.
One point also deserves to be raised: some leukopathies that appear vascular may actually correspond to other pathologies (inflammatory, infectious, genetic) that mimic a banal vascular injury. This is why a complete neurological assessment, sometimes including a lumbar puncture or genetic analyses, may be proposed in cases of atypical presentation.
The Fazekas 2 stage is neither a condemnation nor an unimportant detail. It is a biological signal that, combined with regular neurological follow-up, rigorous blood pressure control, and careful review of ongoing treatments, allows for the best preservation of autonomy and cognitive abilities over time.